The panel also called on Douglas Throckmorton, MD,, deputy director at the Food and Drug Administration’s Center for Drug Evaluation and Research, for answers regarding delays in the approval of a competing epinephrine auto-injector.
“There is justified outrage from families and schools across the country struggling to afford the high cost of EpiPens,” committee Chairman and Rep. Jason Chaffetz (R-Utah) and Rep. Elijah Cummings (D-Md.) said in a statement.
The Senate Permanent Select Subcommittee on Investigations has also opened a preliminary inquiry on Canonsburg, Pa.-based Mylan.
More articles on supply chain:
Market exclusivity main factor in high drug prices, study finds
Supply chain salaries to increase nearly 3% in 2017
5 myths about the EpiPen controversy
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
